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Our group has demonstrated that Th17 cells are
greatly increased in RA synovial fluid compared to RA and
normal peripheral blood (4). Others have shown that the levels
of IL-17 and the percentage of Th17 cells in peripheral blood
correlate with the 28-joint Disease Activity Score (5) at the
onset and during the progression of RA (6). Further, RA
patients who receive disease-modifying antirheumatic drugs
(DMARDs) plus neutralizing antibody against IL-17 achieve a
response according to the American College of Rheumatology
20% improvement criteria (7) more rapidly than do those
receiving DMARDs alone (8). As in RA, post-onset treatment
with neutralizing antibody to IL-17 reduces the severity of CIA
(9). This evidence suggests that IL-17 has important clinical
implications in RA as well as in CIA.
It has been shown that IL-27 is present in RA synovial
fluid and synovial tissue (1,4). However, for IL-27 to effectively
suppress Th17 cell differentiation, high levels of this factor are
required in the early phase of RA, prior to IL-17 secretion
from mature Th17 cells. Consistently, in studies of CIA and
AIA (1,2), post-onset treatment with IL-27 did not affect
disease progression due to its inability to reduce differentiated
Th17 cell numbers. Therefore, use of IL-27 as a therapeutic
agent in RA may be limited to patients whose disease is in an
early stage and may not be useful in patients with established
disease.
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A possible role of leptin-associated increase in soluble
interleukin-2 receptor diminishing a clinical response
to infliximab in rheumatoid arthritis: comment on the
article by Klaasen et al
To the Editor:
We read with great interest the article by Klaasen et al
(1), who reported that rheumatoid arthritis (RA) patients who
have a high body mass index (BMI) exhibited a diminished
clinical response to infliximab treatment, and that adipose
tissue could play a role in the pathophysiology of RA. How-
ever, they did not suggest possible mechanisms.
We speculate that soluble interleukin-2 receptor (sIL-
2R), a marker of T lymphocyte activation, might influence the
clinical response to infliximab in RA patients. Although it has
not yet been extensively studied, Kuuliala et al recently dem-
onstrated that low baseline sIL-2R levels may be predictive of
a rapid clinical response in patients with conventional
treatment–refractory RA being treated with infliximab (2).
Also, it has been reported that human leptin enhanced the
proliferation and activation of circulating T lymphocytes in a
dose-dependent manner, by stimulating the synthesis of IL-2
(3). Because leptin concentrations are positively correlated
with the BMI (4), it is possible that obese RA patients have
increased leptin levels, which could activate circulating T
lymphocytes (increased IL-2 and sIL-2R), thus resulting in a
diminished clinical response to infliximab.
Furthermore, we wonder about the percentage of
smokers in each BMI group in the study by Klaasen et al (1),
because smoking can increase sIL-2R levels (5), which might
affect the clinical response to infliximab (6) and act as a
confounding factor. Recently, Abhishek et al demonstrated
that anti–tumor necrosis factor  (anti-TNF) agents were less
effective in the treatment of RA in current smokers (6), and we
speculate that this might also be due to levels of sIL-2R that
were increased because of smoking (5).
It has been shown that anti-TNF therapy does not
modulate leptin in patients with severe RA (7). We thus
speculate that the IL-2–sIL-2R system might not be influenced
by infliximab itself, but instead by serum leptin levels associ-
ated with BMI.
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Therefore, it would be of interest to measure serum
leptin and sIL-2R levels and ascertain smoking status in
addition to BMI when evaluating the clinical response to
infliximab. Further studies are needed to investigate our
speculations on the possible role of leptin as well as the
potential effect of racial differences, as white patients have
previously been shown to have significantly higher sIL-2R
levels than black patients (mean 455 units/ml versus 365
units/ml; P  0.001) (5).
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Reply
To the Editor:
We would like to thank Dr. Shin and colleagues
for their interest in our work. Based on circumstantial evi-
dence, they suggest that activation of T cells in response to
leptin might result in diminished clinical improve-
ment in obese patients treated with infliximab. It should
be noted that leptin may also stimulate monocytes (1), and
together, these may promote a proinflammatory state (2). We
previously found that increased inflammation in RA syno-
vial tissue is predictive of a better response to infliximab
treatment (3–5). Based on these findings, we would not pre-
dict that a state of increased inflammation is related to a
decreased clinical response, but we cannot exclude the possi-
bility that results may be different in peripheral blood com-
pared to the synovium. We can only resolve this interesting
issue in future studies by directly examining the relationship of
obesity, leptin, and sIL-2R with the clinical response to
infliximab treatment.
Smoking can increase sIL-2R levels and has been
associated with a diminished clinical response to anti-
TNF therapy, which led Dr. Shin and colleagues to ques-
tion whether smoking was a possible confounder in our
study. The percentages in each BMI group of patients who
smoked were 26% in responders (Disease Activity Score
in 28 joints [DAS28] 1.2) and 31% in nonresponders
(DAS28 1.2). When smoking status at baseline was in-
cluded in the statistical analysis, no influence on our results
was found.
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